REG - Ergomed plc - Award of share options
RNS Number : 3455TErgomed plc03 July 2018PRESS RELEASE
Ergomed award of share options to Directors and Company Secretary
London, UK - 3 July 2018: Ergomed plc, (LSE:ERGO) ("Ergomed" or the "Company") a company focused on providing specialised services to the pharmaceutical industry, today announces that the following LTIP (Long Term Investment Plan) awards have been made to newly-appointed CFO Stuart Jackson, COO Jan Petracek, and General Counsel and Company Secretary Sanja Juric.
The awards consist of share options over the Company's ordinary shares having a nominal value of 1 pence each (the "Options") with an exercise price of 1 pence per share. Of the total, 50% of the Options will vest after three years and are not subject to performance criteria. The remaining 50% will vest based on total shareholder return over the three year vesting period with a minimum of 15 per cent. per annum. Once vested the options will be exercisable until 1 July 2028.
Director / Executive
Award of Options
Resulting interest in options
Current shareholding in the Company
Stuart Jackson,
Chief Financial Officer
400,000
400,000
1,845
Jan Petracek, Chief Operations Officer
400,000
450,000
418,006
Sanja Juric, General Counsel and Company Secretary *
25,000
175,000
Nil
* Sanja Juric also holds 150,000 options over shares owned by Dr Miroslav Reljanovic.
In total 825,000 Options were granted yesterday, representing 1.8 per cent. of the issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
1) Stuart Jackson
2) Jan Petracek
3) Sanja Juric
2
Reason for the notification
a)
Position/status
1) Chief Financial Officer
2) Chief Operations Officer
3) General Counsel and Company Secretary
b)
Initial notification /Amendment
1) Initial Notification
2) Initial Notification
3) Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Ergomed Plc
b)
Legal Entity Identifier
213800BVS8I9VMC1AP84
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary shares of 1 pence each
GB00BN7ZCY67
b)
Nature of the transaction
Award of options
c)
Currency
GBP
d)
Price(s) and volume(s)
Price(s)
Volume(s)
1) Nil
400,000
2) Nil
450,000
3) Nil
175,000
e)
Aggregated information
- Aggregated volume
- Price
- Aggregated total
1) 400,000 ordinary shares of 1 pence each, nil consideration
2) 450,000 ordinary shares of 1 pence each, nil consideration
3) 175,000 ordinary shares of 1 pence each, nil consideration
f)
Date of the transaction
03 July 2018
g)
Place of the transaction
Outside a trading venue
ENDS
Enquiries:
Ergomed plc
Tel: +44 (0) 1483 503 205
Stephen Stamp (Chief Executive Officer)
Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black (Joint Broker)
N+1 Singer
Tel: +44 (0) 20 7496 3000
Aubrey Powell (Joint Broker)
Consilium Strategic Communications - for UK enquiries
Tel: +44 (0) 20 3709 5700
Chris Gardner / Mary-Jane Elliott
Ivar Milligan / Olivia Manser
ergomed@consilium-comms.com
MC Services - for Continental European enquiries
Tel: +49 211 5292 5222
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDMSCSSIEFEFASEDW
Recent news on Ergomed
See all newsREG - Ergomed plc - Cancellation of admission to trading of shares
AnnouncementREG - AIM Ergomed plc - Cancellation - Ergomed plc
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG-Millennium Partners, L.P. Form 8.3 - Ergomed plc
AnnouncementREG - BlackRock Group Ergomed plc - Form 8.3 - Ergomed plc
Announcement